EU and US could reach trade deal this weekend - Reuters
On Wednesday, Truist Securities maintained its Buy rating on Bristol-Myers Squibb Co. (NYSE:BMY) with a price target of $65.00. According to InvestingPro data, the stock is currently trading at $48.56, suggesting potential upside based on analyst targets ranging from $36 to $70. The company’s shares have declined nearly 10% year-to-date, though InvestingPro’s Fair Value analysis indicates the stock is undervalued. The firm’s analysts addressed the recent clinical trial setbacks, specifically the Phase 3 trial of Cobenfy, which is already approved for schizophrenia treatment. The trial, named ARISE, did not meet the statistical significance on the primary endpoint, which is the Positive and Negative Syndrome Scale (PANSS) total score, when used as an adjunctive treatment to atypical antipsychotics. Despite these challenges, Bristol-Myers maintains strong fundamentals with a gross profit margin of 75% and healthy current ratio of 1.25.
The failure of Cobenfy in the ARISE trial is expected to exert downward pressure on Bristol-Myers Squibb’s stock. This event follows another recent trial failure, ODYSSEY, in non-obstructive hypertrophic cardiomyopathy (nHCM), which has contributed to concerns over the pharmaceutical company’s near-term prospects.
Despite these challenges, Truist Securities’ analysts anticipate that the stock might face some headwinds until further information is provided by Bristol-Myers Squibb regarding Cobenfy’s future development pathway. The analysts have factored in peak sales for Cobenfy at $6.9 billion, which aligns with the consensus estimate. They also noted that every $1 billion deviation from the peak sales forecast could alter their discounted cash flow (DCF) valuation by approximately $3 per share.
The focus now turns to Bristol-Myers Squibb’s next steps as they navigate through the recent trial disappointments. The company’s management is expected to offer more clarity on their strategic plans for Cobenfy and its impact on the company’s financial outlook. Meanwhile, Truist Securities stands by its positive rating and price target, suggesting confidence in the overall value proposition of Bristol-Myers Squibb’s stock. Notably, the company has maintained dividend payments for 55 consecutive years, with a current dividend yield of 5%. For deeper insights into BMY’s financial health and additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and the exclusive Pro Research Report.
In other recent news, Bristol-Myers Squibb reported mixed results from its Phase 3 ARISE trial for Cobenfy, a potential adjunctive treatment for schizophrenia. The primary endpoint of achieving statistical significance in improving symptoms was not met, although some numerical improvement was observed. Despite this, Jefferies maintained a Buy rating on the company, though it reduced the price target from $70 to $68 due to these trial results. Meanwhile, Cantor Fitzgerald and Goldman Sachs both have a Neutral rating on the stock with a $55 price target, noting challenges such as competition and the impact of Medicare Part D redesign.
BMO Capital Markets also maintained a Market Perform rating with a $61 price target after Bristol-Myers’ ODYSSEY-HCM Phase 3 trial for Camzyos did not meet its primary endpoint. This setback may complicate the company’s growth as it faces upcoming patent expirations. Analysts from these firms highlighted the importance of upcoming trial results and strategic responses to these challenges. Bristol-Myers Squibb’s focus remains on navigating these hurdles while enhancing its growth portfolio. Investors are closely monitoring the company’s next steps, particularly in light of the recent clinical trial outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.